Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY)

Harmony Biosciences Holdings, Inc., a company that trades under the symbol HRMY on the NASDAQ, operates within the pharmaceutical industry. The company is dedicated to developing and commercializing innovative therapies for patients afflicted with rare neurological diseases.

Harmony Biosciences' primary business activity revolves around the development and commercialization of innovative therapies for rare neurological diseases. The company's operations are concentrated in the United States, where it has established a significant presence in the narcolepsy market. Narcolepsy is a chronic neurological disorder that affects approximately 170,000 Americans, with fewer than 50% diagnosed. The disorder is characterized by excessive daytime sleepiness, cataplexy, hallucinations, sleep paralysis, and disrupted nighttime sleep.

The company's revenue is primarily generated through the sale of WAKIX, its flagship product approved by the FDA for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and cataplexy in adult patients with narcolepsy. WAKIX is a first-in-class molecule with a novel mechanism of action that increases histamine signaling in the brain by binding to H3 receptors. It is available in tablet form and is taken once daily in the morning upon waking. Harmony Biosciences has a dedicated sales team of over 80 professionals who call on approximately 9,500 healthcare providers (HCPs) who treat more than 90% of narcolepsy patients in the United States.

In the narcolepsy market, Harmony Biosciences has a significant presence and a strong competitive advantage due to its novel mechanism of action, non-scheduled status, and ability to be taken as monotherapy or concomitantly with other narcolepsy medications. Traditional treatments for narcolepsy, such as stimulants and wake-promoting agents, have significant side effects and are often associated with abuse and dependence. WAKIX's unique mechanism of action differentiates it from these traditional treatments, making it a safer and more tolerable option for patients.

Harmony Biosciences' pipeline includes pitolisant, a molecule with a novel mechanism of action that regulates histamine and histaminergic signaling. Pitolisant is being evaluated for the treatment of idiopathic hypersomnia, Prader-Willi syndrome, and myotonic dystrophy. Additionally, the company has acquired Zynerba Pharmaceuticals, a clinical-stage pharmaceutical company focused on innovative pharmaceutically produced transdermal cannabidiol therapies for orphan neuropsychiatric disorders, including Fragile X syndrome.

In terms of financial performance, Harmony Biosciences has reported strong revenue growth driven by the commercialization of WAKIX. The company has a strong balance sheet, with cash, cash equivalents, and investments on hand of $240 million as of December 31, 2023.